These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 30856589)
1. Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy. Domínguez-Ríos R; Sánchez-Ramírez DR; Ruiz-Saray K; Oceguera-Basurto PE; Almada M; Juárez J; Zepeda-Moreno A; Del Toro-Arreola A; Topete A; Daneri-Navarro A Colloids Surf B Biointerfaces; 2019 Jun; 178():199-207. PubMed ID: 30856589 [TBL] [Abstract][Full Text] [Related]
2. Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles. Colzani B; Pandolfi L; Hoti A; Iovene PA; Natalello A; Avvakumova S; Colombo M; Prosperi D Int J Nanomedicine; 2018; 13():957-973. PubMed ID: 29491709 [TBL] [Abstract][Full Text] [Related]
3. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Sun B; Ranganathan B; Feng SS Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985 [TBL] [Abstract][Full Text] [Related]
4. Development and characterization of hyaluronic acid modified PLGA based nanoparticles for improved efficacy of cisplatin in solid tumor. Alam N; Koul M; Mintoo MJ; Khare V; Gupta R; Rawat N; Sharma PR; Singh SK; Mondhe DM; Gupta PN Biomed Pharmacother; 2017 Nov; 95():856-864. PubMed ID: 28903181 [TBL] [Abstract][Full Text] [Related]
5. Dual-Targeted Delivery of Nanoparticles Encapsulating Paclitaxel and Everolimus: a Novel Strategy to Overcome Breast Cancer Receptor Heterogeneity. Houdaihed L; Evans JC; Allen C Pharm Res; 2020 Jan; 37(3):39. PubMed ID: 31965330 [TBL] [Abstract][Full Text] [Related]
6. Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies. Koopaei MN; Dinarvand R; Amini M; Rabbani H; Emami S; Ostad SN; Atyabi F Int J Nanomedicine; 2011; 6():1903-12. PubMed ID: 21931485 [TBL] [Abstract][Full Text] [Related]
7. Development of High-Loading Trastuzumab PLGA Nanoparticles: A Powerful Tool Against HER2 Positive Breast Cancer Cells. Caputo TM; Barisciano G; Mulè C; Cusano AM; Aliberti A; Muccillo L; Colantuoni V; Sabatino L; Cusano A Int J Nanomedicine; 2023; 18():6999-7020. PubMed ID: 38034948 [TBL] [Abstract][Full Text] [Related]
8. Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer. Mi Y; Zhao J; Feng SS J Control Release; 2013 Aug; 169(3):185-92. PubMed ID: 23403395 [TBL] [Abstract][Full Text] [Related]
9. Selective Cytotoxicity to HER2 Positive Breast Cancer Cells by Saporin-Loaded Nanobody-Targeted Polymeric Nanoparticles in Combination with Photochemical Internalization. Martínez-Jothar L; Beztsinna N; van Nostrum CF; Hennink WE; Oliveira S Mol Pharm; 2019 Apr; 16(4):1633-1647. PubMed ID: 30817164 [TBL] [Abstract][Full Text] [Related]
10. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles. Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347 [TBL] [Abstract][Full Text] [Related]
11. Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells. Cirstoiu-Hapca A; Buchegger F; Bossy L; Kosinski M; Gurny R; Delie F Eur J Pharm Sci; 2009 Oct; 38(3):230-7. PubMed ID: 19632322 [TBL] [Abstract][Full Text] [Related]
12. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab. Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986 [TBL] [Abstract][Full Text] [Related]
13. Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy. Wang H; Jia D; Yuan D; Yin X; Yuan F; Wang F; Shi W; Li H; Zhu LM; Fan Q J Nanobiotechnology; 2021 May; 19(1):138. PubMed ID: 33985511 [TBL] [Abstract][Full Text] [Related]
14. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice. Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607 [TBL] [Abstract][Full Text] [Related]
15. A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy. Guo Y; Wang XY; Chen YL; Liu FQ; Tan MX; Ao M; Yu JH; Ran HT; Wang ZX Acta Biomater; 2018 Oct; 80():308-326. PubMed ID: 30240955 [TBL] [Abstract][Full Text] [Related]
16. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells. Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563 [TBL] [Abstract][Full Text] [Related]
17. Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer. Bull-Hansen B; Berstad MB; Berg K; Cao Y; Skarpen E; Fremstedal AS; Rosenblum MG; Peng Q; Weyergang A Oncotarget; 2015 May; 6(14):12436-51. PubMed ID: 26002552 [TBL] [Abstract][Full Text] [Related]
18. Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells. Truffi M; Colombo M; Sorrentino L; Pandolfi L; Mazzucchelli S; Pappalardo F; Pacini C; Allevi R; Bonizzi A; Corsi F; Prosperi D Sci Rep; 2018 Apr; 8(1):6563. PubMed ID: 29700387 [TBL] [Abstract][Full Text] [Related]
19. Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles. Satpathy M; Wang L; Zielinski RJ; Qian W; Wang YA; Mohs AM; Kairdolf BA; Ji X; Capala J; Lipowska M; Nie S; Mao H; Yang L Theranostics; 2019; 9(3):778-795. PubMed ID: 30809308 [TBL] [Abstract][Full Text] [Related]